Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

- PMLiVE

ViCentra appoints Reman McDonagh as Vice President, Global Marketing

McDonagh has held senior leadership positions at Roche, Medtronic, Cellnovo and Insulet

- PMLiVE

Designing healthcare AI that works for every patient

As generative AI becomes more embedded in clinical decision-making, ensuring safety, accuracy and relevance is critical

- PMLiVE

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses

- PMLiVE

TECregen appoints Klaas P Zuideveld as CEO

Zuideveld was most recently CEO of Versameb, and has held senior roles at Caris Life Sciences and Roche

- PMLiVE

Shaping the future of healthcare communications

Introducing the 2026 Communiqué Awards

Cuttsy+Cuttsy employees

Cuttsy+Cuttsy becomes employee owned

Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.

Cuttsy + Cuttsy

- PMLiVE

Celebrating Excellence in Healthcare Partnerships Awards!

The Awards were sponsored by Inizio, Chase, druid and Robotics AI

- PMLiVE

Indegene appoints Jill DeSimone to Board of Directors

DeSimone was formerly President of US Oncology at Merck

- PMLiVE

Oral health and systemic disease: why they may be more closely linked than we thought

P. gingivalis, a type of bacteria found in the mouth, is linked to autoimmune diseases like rheumatoid arthritis

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links